Previous investigations of patients with gestational trophoblastic neoplasia have shown that their urines often contain carboxyterminal peptide (C1TP) fragments of the choriogonadotropin (hCG) ,8-subunit as well as forms of hCG deficient in sialic acid. In order to determine whether 8-CTP fragments are among the urinary products of the peripheral degradation of desialylated hCG (as-hCG), using a continuous infusion technique, we gave highly purified as-hCG to humans. Six healthy subjects were given a loading dose of 0.8 mg of as-hCG followed by an infusion of the same preparation. An overall mean infusion rate of 62.9 gg/min was maintained for 6 h, and the mean serum concentration of as-hCG achieved during the infusion was 72.1 ng/ml. In all six subjects, l-C'TP fragments were the predominant immunoreactive forms of as-hCG in urine obtained during the infusion. In contrast, the urine of subjects infused with hCG has been shown to contain hCG itself, but nil l-CTP fragments or as-hCG. After the as-hCG infusion was stopped, the excretion of the /3-CTP fragments in urine declined rapidly. There were no ,8-ClP fragments detectable in sera obtained during the infusion or in sera incubated with as-hCG at 37°C. After incubation with as-hCG for 4 h, the urine of normal subjects contained small amounts of fl-CTP fragments; however, the apparent proteolytic activity was too low to account for either the quantity of fl-CTP fragments produced during the infusion or the extremely low levels of ashCG in the urine. These data demonstrate the existence in humans of a peripheral metabolic pathway that cleaves fl-CT? fragments from as-hCG and allows their excretion in urine. Thus, the frequent presence of,-CTP fragments in the urines of patients with gestational trophoblastic neoplasia can be accounted for in part by the metabolism of the forms of hCG that bear an altered carbohydrate structure, which are prevalent in this disease.
Introduction
Several investigations have given evidence for a disparity between the forms of human choriogonadotropin (hCG)' trophoblast (1) (2) (3) (4) (5) (6) (7) . The abnormal forms of hCG and their metabolites are of clinical interest as potential molecular markers of the malignant transformation of the trophoblast. Recently, we have reported identification of two novel types of hCG-related molecules, which occur commonly in the urines of patients with gestational trophoblastic neoplasia but rarely in the urines of pregnant women (8) . The first type consists of fragments of the hCG (3-subunit that lack the conformational antigenic determinant required for cross-reactivity in the ,3-core radioimmunoassay (RIA) (SB6 antiserum), but retain the (3-carboxyterminal peptide (CTP) antigenic determinant. The second type consists of desialylated forms of hCG that cross-react in a RIA that requires galactose-terminated O-serine carbohydrate in the fl-CTP region (8, 9) . Since neither desialylated forms of hCG nor fl-CTP fragments were found in the urine of normal subjects after infusion of highly purified hCG (8-10), we hypothesized that CTP fragments of the hCG /-subunit could be products of the metabolism of abnormal forms of hCG, such as those deficient in sialic acid. We tested this hypothesis by analyzing the urines of healthy subjects who were given an infusion of asialo-hCG (as-hCG). We found that (3-CTP fragments are indeed urinary products of the peripheral metabolism of as-hCG.
Methods
Preparation of desialylated hCG. Highly purified hCG (batch CR121) was desialylated and characterized biologically and physicochemically as previously reported (1 1). The desialylated preparation was processed for human administration by Millipore filtration (Millipore Corp., Bedford, MA).
Subjects. Six healthy volunteers, three men and three women, aged 21-67 yr, were given an infusion of as-hCG after a loading dose of 0.8 mg injected intravenously. A continuous infusion of 350 ml of 0.9% NaCl, containing as-hCG and 2 ml of 25% human serum albumin, was maintained at a flow rate of 50 ml/h for 6 h. An aliquot of the infusate given to each subject was stored at -20°C. A blood sample was withdrawn from the contralateral arm each hour during the infusion. Urine specimens were collected every 2 h during the 6 h of infusion and 6, 12, and 24 h thereafter. Sera and aliquots of the urine collections were stored at -20°C.
Radioimmunoassays (RIAs). RIAs were carried out employing antisera directed toward the hCG #3-core (SB6) and hCG ,B-CTP (R525) antigenic determinants; these RIAs have been previously characterized (12, 13) . The same as-hCG preparation as given to the subjects was used as the reference preparation and the radioligand in the RIAs.
Iodination of as-hCG with ['25I]iodide was performed by using the chloramine T method, and the specific activity of the '25I-as-hCG was 50-75 gCi/Ag. Normal male serum and urine were used to compensate for nonspecific effects in the RIAs when sera or urines were assayed directly. RIA potencies were expressed in terms of mass of the highly purified as-hCG preparation. The least detectable doses per tube were -0.2 and 1.0 ng in the 3-core and fl-CTP RIA, respectively. Figure 1 . Sephadex G-100 gel filtration of urine specimens collected from subject 4 between 4 and 6 h (top), from subject I between 2 and 4 h (middle), and from subject 6 between 0 and 2 h (bottom) during the infusion of as-hCG. A 2-ml aliquot of untreated urine was filtered and the eluted fractions were assayed for Swcore immunoreactivity in using the SB6 antiserum and for jflCTP immunoreactivity in using the R525 antiserum. Fractions obtained from filtration of preinfusion urine contained no detectable S-core or #-CTP immunoreactivity. A, hCG fl-CTP; *, hCG S-core. infusion time (Fig. 3 ). This individual stood out in another respect-his urine output was the highest (245 ml/h) of the group (145±54 ml/h, mean±SD). Kinetics of excretion of urinary fl-CTP fragments. To explore the timing of the excretion of fl-CTP in relationship to the as-hCG infusion, the concentrations of both fl-CTP and 13-core immunoreactivities were measured in urines collected during and after the infusion. In that the urine volumes varied between the subjects at different times, the excretion rates in nanograms per hour of both immunoreactivities were determined for each subject. Excretion of 13-CTP immunoreactivity in the urine occurred as early as the first 2 h of the as-hCG infusion (upper panel, Fig. 4) . The average excretion rate remained fairly constant (-1,200 ng/h) during the infusion period (Fig. 4, upper panel) ; and on a molar basis, it appeared to exceed the excretion rate of 1-core immunoreactivity by a factor of about 6 (compare upper and lower panels, Fig. 4 ). This disparity between the urinary excretion of 13-CTP and 13-core immunoreactivities, added to their elution patterns on the Sephadex G-100 column (Figs. 1-3) , shows that on the average, >80% of the 13-CTP immunoreactivity in urines obtained during the infusion consisted of 13-CTP fragments. At the end of the infusion the excretion rate of 13-CTP immunoreactivity rapidly decreased, becoming undetectable in urines collected 6 h after stopping the infusion (Fig. 4 , upper panel). In contrast, the excretion rate of 1-core immunoreactivity peaked in the urines collected 6-18 h after stopping the infusion (Fig. 4, lower panel) . This delayed pattern of excretion of 13-core immunoreactivity is reminiscent of results obtained with the hCG 13-subunit (18).
Metabolic and renal clearance rates ofas-hCG. Continuous infusion of as-hCG after the 0.8-mg bolus produced serum levels of as-hCG that remained quite stable from the 1st to the 6th h of infusion. The mean as-hCG level in the sera was similar among the six subjects (Table I) ; they averaged 72.1 ng/ml with an overall mean infusion rate of 62.9 gg/min.
The mean MCR of as-hCG was 494.9±96.6 ml/min M2 (mean±SD). Using a single injection technique to estimate the MCR of as-hCG, we obtained a value of 349±96 ml/minm2, previously (1 1). Both of these values for the MCR of as-hCG are several orders of magnitude greater than that for hCG (1.88±0.08 ml/min m2 (14) .
Based on the total amount of 13-CTP immunoreactivity excreted during the 6-h infusion and the amount of 13-CTP immunoreactivity eluting in the position of as-hCG (Figs. 1-3) , we estimated that the RCR of the as-hCG itself was less than 0.615 ml/h-M2. In contrast, the renal clearance rate of intact hCG is 24 ml/h * m2 (14) or at least 39-fold greater than that of as-hCG. Thus, the renal processing of as-hCG is radically different from that of native hCG.
The mean total amounts of 13-CTP and 13-core immunoreactivities excreted over the 48 h were 9.2 and 12.6 ug, respectively. This is equivalent to -0.05% of the total amount of as-hCG immunoreactivity infused into each subject (22.9 mg) over the 6-h period. These data demonstrate that renal excretion of as-hCG, 13-core fragments, and 13-CTP fragments with immunoreactivity actually contributes little to the overall metabolic disposal, and therefore the MCR, of the as-hCG molecule. The renal excretion of native hCG, on the other hand, accounts for 21.7% of its disposal (14 detectable fl-CTP fragments ( Fig. 5 and 6 ). In three of the subjects, the serum f-core and fl-CTP immunoreactivities eluted in the same position as the '25I-as-hCG (Fig. 5) . In two other subjects, the major peak of f-core immunoreactivity also eluted in the position of '25I-as-hCG; and there was a minor peak of f-core immunoreactivity in the region of small molecular size (Fig. 6 ), but there were no fl-CTP fragments evident. Based on the area under the eluted peaks, these S-core fiagments constituted -18% of the total f-core immunoreactivity in the eluate. The fl-core fragments appeared in the elution profiles of the 6 h serum specimens of only two of the five subjects. Figure S . Sephadex G-I00 gel filtration of sera obtained from subject 3 (top), subject 1 (middle), and subject 4 (bottom) after 6 h of infusion of as-hCG. A 2-ml aliquot of each sample was filtered and the eluted fractions were assayed as described in the legend of Fig. 1 . A, hCG fl-CTP; ., hCG f-core. incubated different concentrations of as-hCG with normal urines at 370C for 4 h. After storage under the same conditions as the urines obtained during the study, the samples were assayed by using the f-core and the ,6-CTP RIAs. If incubated at a concentration of 1 gg/ml as-hCG, the as-hCG immunoreactivities recovered were 0.89±0.06 gg/ml and 0.83±0.04 jig/ml (mean±SD of six determinations) in f-core and fl-CTP RIAs, respectively; and if incubated at a concentration of 0.66 jig/ml, the amounts recovered were 0.62±0.02 jig/ml and 0.59±0.03 jg/ml, respectively. The urinary immunoreactivity eluted from the Sephadex G-100 column mainly in the position of the '251-as-hCG marker. There was fl-CTP immunoreactivity clearly detectable in the position of the fl-CTP fragments (Fig.  7, upper panel) . However, compared to the quantity of f-CTP fragments evident in the urine during the infusion of as-hCG (Fig. 1) , the quantity generated from as-hCG in the urine during processing was quite low.
To estimate the recovery of as-hCG by the acetone concentration procedure, 50, 100, and 200 jg of as-hCG were added to three urine specimens and the acetone extracts were prepared. The mean recoveries of f-core and fl-CTP immunoreactivities in the concentrates were 59 and 66%, respectively (Table II) . As expected, the elution profile on Sephadex G-100 ., hCG 3-core. showed the presence of a small amount of f3-CTP fragments in the concentrate (Fig. 7, lower panel) .
Although fl-CTP fragments were not detected in the sera, it appeared possible that they could be generated therein and rapidly cleared by the kidney and excreted in the urine. However, the contribution of serum proteolysis to the generation of f3-CTP fragments is nil, as incubation of as-hCG with normal serum at 370C for 3 h did not generate any detectable 13-CTP fragments (1 1).
Discussion
Previously, we reported that hCG fl-CTP fragments were present in the urines of patients with choriocarcinoma but not in those of normal pregnancy (8) . In that the f3-CTP fragments were often associated with unusual forms of hCG that were desialylated in the fl-CTP region, we formulated the hypothesis that these fragments could be degradation products of the unusual forms of hCG. Indeed, in the present study, we found evidence for the existence in humans of a peripheral metabolic pathway that cleaves fl-CTP fragments from as-hCG. Healthy subjects that were given an infusion of as-hCG excreted 13-CTP immunoreactive material of molecular size smaller than simply by proteolytic cleavage in the urine. The latter process would be expected to yield the fragments in the same timeframe. Hence, as-hCG processing by urine per se appears not to be responsible for the production of the fl-CTP fragments. Evidently, tissue proteases are involved.
In vitro studies have demonstrated that as-hCG binds to human membrane preparations of liver, kidney, and thyroid tissue (24-26). Both in vitro and in vivo animal data indicate that the liver is the major tissue for the removal of asialoglycoproteins from the circulation (27) (28) (29) (30) . In humans, however, metabolism of as-hCG within the kidney could be quantitatively more important than it is in animals; the affinity of human kidney membranes for as-hCG has been reported to be nearly the same as that of human hepatic membranes (25) . Even though hepatic tissues (or others) theoretically could contribute to the production of the fl-CTP fragments that we detect in urine, several other observations are consistent with proteolysis within the kidney being a major factor: (a) Studies in rats indicate that catabolism of glycoprotein hormones occurs in the kidney (31, 32) , and as-hCG is no exception in this regard (Lefort, G. P., J. M. Stolk, and B. C. Nisula, unpublished observation) (33) . (b) The RCR of as-hCG is <2.56% that of intact hCG, whereas presumably the amount of as-hCG filtered at the glomerulus is, if anything, greater than the amount of hCG, in that as-hCG is the smaller molecule. Thus, the renal tubular epithelium appears to be processing more filtered ashCG than filtered hCG. (c) Urine alone was capable of cleaving (3-CTP fragments from as-hCG, albeit relatively inefficiently. The presumed protease may well be renal in origin in that serum exhibited no such activity. (d) During the infusion of as-hCG in humans, although fl-CTP fiagments were consistently present in the urine, they were not detectable in the serum. If ,3-CTP fragments were generated in tissues other than the kidney and released into the serum, their RCR would have to be more than several orders of magnitude greater than that of as-hCG to explain the accumulation of,B-CTP fragments in urine. Collectively, these data are consistent with the idea of cleavage of as-hCG by the renal tubular epithelium with escape of ,B-CTP fragments into urine. However, to establish the precise mechanism by which the body processes as-hCG and generates the fl-CTP fragments, further investigations will be necessary.
In the present study, the quantity of (3-core fragments excreted in the first hours of the infusion was relatively low, but increased dramatically 6-18 h after stopping the infusion at 6 h, whereas the excretion rate of,B-CTP fragments was relatively high during the infusion and decreased rapidly thereafter. The delayed excretion of (-core fragments has been reported to occur in the urine of normal subjects after a single intravenous injection of hCG (3-subunit (18), suggesting that hCG-related molecules can be processed by the tissues and subsequently released. Although the kidney seems to be one likely site for this process, other tissues such as the liver, may be involved. Indeed, in the present study, we found (3-core fragments in the sera of two subjects at the 6th h of the infusion. It is possible that (3-core fragments, once generated in the liver, could be released into the circulation, cleared by the kidney, and excreted in the urine. Investigations of the metabolism of as-hCG in the rat have revealed that, although about 90% of injected as-hCG was taken up by the liver within 7 min, the hepatic processing of this molecule resulted in the production of (-core fragments which displayed an intracellular half-life that exceeded 5 h (34). Thus, it is conceivable that the appearance of 3-core fragments in the serum after 6 h of infusion of as-hCG represents the release of long-lived 3-core fragments from the human liver, a presumed major site of ashCG degradation.
